Story

PepsiCo to End Coverage for Weight-Loss Drugs Like Wegovy, Zepbound Citing Costs

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20261 min read
PepsiCo to End Coverage for Weight-Loss Drugs Like Wegovy, Zepbound Citing Costs
Text size
Background

PepsiCo Inc. (NASDAQ:PEP) plans to stop covering popular weight-loss drugs in its employee health insurance plans beginning in October, citing the rapidly increasing expense of these treatments, according to a report from Bloomberg.

A Cost-Driven Decision

In an email to some employees reviewed by Bloomberg News, the company stated that the change was necessary to manage costs. The email, sent by pharmacy benefit manager Express Scripts, a unit of Cigna Group (NYSE:CI), noted that prescription weight-loss medications have become one of the fastest-growing costs in PepsiCo's health plans.

"Removing coverage for prescription weight-loss drugs enables us to maintain a healthcare program that is sustainable and affordable for all PepsiCo employees," the communication said, according to the report. The decision affects blockbuster GLP-1 drugs such as Wegovy from Novo Nordisk A/S (NYSE:NVO) and Zepbound from Eli Lilly & Co. (NYSE:LLY).

Broader Industry Trend

Sample IUX Markets – In-articleAd

PepsiCo's move is not an isolated event but reflects a wider trend among U.S. employers and insurance providers. Many are re-evaluating or scaling back coverage for this new class of highly effective but expensive anti-obesity medications.

While demand for these drugs remains exceptionally high, their long-term cost has become a significant concern for the entities that pay for them. This creates a challenging dynamic for pharmaceutical companies, which are seeing massive revenue growth but also facing increasing pushback from payers on pricing and reimbursement.

Implications for Employees

Under the new policy, PepsiCo employees who wish to continue using these medications will need to pay for them outside of the company's insurance plans. The email reportedly suggested that alternative payment options may be available, stating that "many commonly used weight-loss medications now have cash-pay affordability pathways that were not available previously to individual patients."

Read next

More on Stocks
Back to latest news

LATEST